Pfizer UK

Gender Pay Gap Backslides Within European Healthcare Industry

Retrieved on: 
Tuesday, March 14, 2023
Workplace, Optimism, HBA, Healthcare Businesswomen's Association, Pfizer UK, Great Resignation, Research, Gender pay gap, Woman, Healthcare industry, Employment, Volunteering, News, United Kingdom, Nursing, Management, Video game, Health care

FAIRFIELD, N.J., March 14, 2023 /PRNewswire/ -- Results from a new report, "Reducing the Gender Pay Gap to Drive Success in the Healthcare Industry," issued by the Healthcare Businesswomen's Association (HBA) Europe region in collaboration with our data partner reveals an increase in the gender pay gap between men and women in the life sciences sector in Europe. With input from more than 50,000 employees at 180 companies, the data show that the median pay gap increased from 11.5 percent to 14.4 percent in the past two years.

Key Points: 
  • FAIRFIELD, N.J., March 14, 2023 /PRNewswire/ -- Results from a new report, "Reducing the Gender Pay Gap to Drive Success in the Healthcare Industry," issued by the Healthcare Businesswomen's Association (HBA) Europe region in collaboration with our data partner reveals an increase in the gender pay gap between men and women in the life sciences sector in Europe.
  • The report data indicates Sweden, Ireland, Netherlands, and Portugal have spearheaded an improvement in the gender pay gap since the 2021 report.
  • However, the largest European markets, like France and the United Kingdom, show a worsening of the pay gap.
  • HBA volunteers spoke with various industry leaders to identify what can be done by individuals, companies, and governments to reverse the current trend of a worsening gender pay gap.

Delix Therapeutics and Pfizer UK Recognized as Gender Equity Champions for Women in the Workplace by Healthcare Businesswomen's Association

Retrieved on: 
Tuesday, September 27, 2022
CableACE Award, HBA, Therapy, Culture, Woman, Brain, Psychiatry, Pfizer UK, Organization, Industry, Environment, Healthcare Businesswomen's Association, DEI, Annual conferences, Health equity, Mental health, Patient, Female, Interim, Workplace, ACE, Human, Advancement, DNA, Conference, Equality, Multimedia, Parity, Ottawa Women's Training and Employment Network, Lists of diseases, Pharmaceutical industry, Management, Pfizer

Gender Equity Champions--Delix Therapeutics and Pfizer UK--Deliver for Women in Healthcare Workplace.

Key Points: 
  • Gender Equity Champions--Delix Therapeutics and Pfizer UK--Deliver for Women in Healthcare Workplace.
  • Engagement (ACE) Awards recognize companies committed to ensuring that gender diversity and leadership opportunities for women are part of their organizational DNA.
  • Like their drive to push the frontiers of neuroplasticity research, Delix Therapeutics is also pushing the standards of gender representation in the workplace.
  • Based in Massachusetts, Delix Therapeutics is a pioneering neuroscience company developing novel neuroplasticity-promoting therapeutics for serious psychiatric and neurological conditions.

Delix Therapeutics and Pfizer UK Recognized as Gender Equity Champions for Women in the Workplace by Healthcare Businesswomen's Association

Retrieved on: 
Tuesday, September 27, 2022
CableACE Award, HBA, Therapy, Culture, Woman, Brain, Psychiatry, Pfizer UK, Organization, Industry, Healthcare Businesswomen's Association, Environment, DEI, Annual conferences, Health equity, Mental health, Patient, Female, Interim, Workplace, ACE, Human, Advancement, DNA, Conference, Equality, Parity, Ottawa Women's Training and Employment Network, Lists of diseases, Pharmaceutical industry, Management, Pfizer

Engagement (ACE) Awards recognize companies committed to ensuring that gender diversity and leadership opportunities for women are part of their organizational DNA.

Key Points: 
  • Engagement (ACE) Awards recognize companies committed to ensuring that gender diversity and leadership opportunities for women are part of their organizational DNA.
  • Like their drive to push the frontiers of neuroplasticity research, Delix Therapeutics is also pushing the standards of gender representation in the workplace.
  • Based in Massachusetts, Delix Therapeutics is a pioneering neuroscience company developing novel neuroplasticity-promoting therapeutics for serious psychiatric and neurological conditions.
  • The gender pay gap is a frequent topic of conversation related to inequities women face in the workplace.

Poseida Therapeutics Appoints Charles M. Baum, M.D., Ph.D., to Board of Directors

Retrieved on: 
Wednesday, May 18, 2022
Odyssey, Stanford University, U.S. Securities and Exchange Commission, George Washington University School of Engineering and Applied Science, Lists of diseases, Private Securities Litigation Reform Act, Twitter, Cancer, Drug discovery, Research and development, Board of directors, Immunology, Genetic engineering, Therapy, American Cancer Society, Worldwide, Patent, Transposase, Coronavirus Scientific Advisory Board (Turkey), SAN, Board, Washington University School of Medicine, Immunomedics, Pfizer UK, Schering-Plough, Mirati, Company, Director, Multimedia, LinkedIn, National, Security (finance), Senior, Nasdaq, Leadership, AAV, Development, CEO, Pharmaceutical industry, Vaccine, Research, Pfizer

Additionally, the Company announced the resignation of David Hirsch, M.D., Ph.D., from its Board of Directors, effective May 17, 2022.

Key Points: 
  • Additionally, the Company announced the resignation of David Hirsch, M.D., Ph.D., from its Board of Directors, effective May 17, 2022.
  • "I am excited to have Chuck join the Board of Directors of Poseida.
  • As a recognized biopharma industry leader, Chuck has developed therapeutics that have transformed the field of oncology," said Mark Gergen, Chief Executive Officer of Poseida Therapeutics.
  • Dr. Baum currently serves as Chairman of the Board at OncoMyx Therapeutics, a member of the Boards of Directors at PMV Pharma and Odyssey Therapeutics, and a member of the Scientific Advisory Board for ALX Oncology.

First of its Kind Coalition Sees Health Industry, Professional Bodies and Experts Come Together to Holistically Tackle ‘Hidden Pandemic’ of Antibiotic Resistant Infections

Retrieved on: 
Monday, February 14, 2022
Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Infectious Diseases, Hospitals, Patient, 1969 White Paper, Genetically modified bacteria, Infection, NHS, Government, Science, AMR, Global health, Pandemic, ABPI, Society, Association of the British Pharmaceutical Industry, Outline, Awareness, Goal, Antimicrobial chemotherapy, Medtech, Neglected tropical diseases, Roche Diagnostics, AMS, Pfizer, Partnership, IMC, Policy, Pharmaceutical industry, Public health, Microbiology, White paper, Accidental Death and Disability: The Neglected Disease of Modern Society, Association, Diagnosis, COVID-19, Vaccination, British Society for Antimicrobial Chemotherapy, Industry, Antimicrobial stewardship, Vaccine, Pfizer UK, the Infection Management Coalition (IMC), antimicrobial stewardship (AMS), antimicrobial resistance (AMR), THE INFECTION MANAGEMENT COALITION (IMC), ANTIMICROBIAL STEWARDSHIP (AMS), ANTIMICROBIAL RESISTANCE (AMR)

Antimicrobial resistance is a growing challenge and an existential threat that we must overcome, says Dr David Jenkins, President of the British Society for Antimicrobial Chemotherapy.

Key Points: 
  • Antimicrobial resistance is a growing challenge and an existential threat that we must overcome, says Dr David Jenkins, President of the British Society for Antimicrobial Chemotherapy.
  • We are encouraged to see for the first time, a diverse range of sectors and industries come together in partnership through this Coalition, to address the critical issue of infection management.
  • We are a wide-ranging coalition of opinion leaders, health professionals and their societies, the scientific community and industry.
  • Given our shared and common goal with the Governments commitments to address this, a unified approach is required.

New Cancer Therapies Continue to Develop and Give Hope in Rapidly Improving Oncology Space

Retrieved on: 
Monday, September 20, 2021
Therapy, Bossard Holding AG, Pembrolizumab, Carboplatin, Hoffmann-La Roche, OTC, City of Hope, Conference, Ageing, Boucekastichus, Squamous cell carcinoma, ONC, Wilms' tumor, Light, City, Breast cancer, Pfizer UK, Optimism, Roche, Disease, Technology, Pfizer, Etoposide, Maintenance, Radiation, Survival, Lead, COTA, BMS, NYSE, Data visualization, Oncology, Neoplasm, Partnership, CURE, Oncolytics Biotech, Patient, NASDAQ, FDA, Cancer, MRK, Bristol Myers Squibb, Kidney cancer, Pelareorep, Trastuzumab, Large-cell lung carcinoma, Risk, BMY, HCP, Trastuzumab emtansine, TSX, News, Immunotherapy, NHS, CO, International Conference on Population and Development, PFE, Pharmaceutical industry, Medical imaging

VANCOUVER, BC, Sept. 20, 2021 /PRNewswire/ -- USA News Group - Oncology data leader COTA recently released a recent survey where half of the respondents pointed to "Operation Warp Speed" as evidence that cancer treatments can and should be moving forward faster. However, in many ways, 2021 has witnessed several major developments that continue to provide optimism within the oncology field, including those from Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC),Roche Holding AG (OTC: RHHBY), Merck &. Co., Inc. (NYSE: MRK), Bristol-Myers Squibb Company (NYSE: BMY), and Pfizer Inc. (NYSE: PFE).

Key Points: 
  • In abscopal tumors, both pelareorep monotherapy and pelareorep-radiation combination therapy led to a statistically significant increase in infiltrating anti-cancer CD8+ T cells.
  • In terms of significance, this effect was not seen with single-agent radiotherapy in either the primary or the abscopal tumors.
  • "This is a compelling finding that has the potential to be broadly applicable across multiple cancer indications and warrants further study.
  • As new Keytruda combinations from Merck emerge, Bristol-Myers Squibb has begun to tout 5-year kidney cancer data for Opdivo-Yervoy.

New Cancer Therapies Continue to Develop and Give Hope in Rapidly Improving Oncology Space

Retrieved on: 
Monday, September 20, 2021
Therapy, Bossard Holding AG, Pembrolizumab, Carboplatin, Hoffmann-La Roche, OTC, City of Hope, Conference, Ageing, Boucekastichus, Squamous cell carcinoma, ONC, Wilms' tumor, Light, City, Breast cancer, Pfizer UK, Optimism, Roche, Disease, Technology, Pfizer, Etoposide, Maintenance, Radiation, Survival, Lead, COTA, BMS, NYSE, Data visualization, Oncology, Neoplasm, Partnership, CURE, Oncolytics Biotech, Patient, NASDAQ, FDA, Cancer, MRK, Bristol Myers Squibb, Kidney cancer, Pelareorep, Trastuzumab, Large-cell lung carcinoma, Risk, BMY, HCP, Trastuzumab emtansine, TSX, News, Immunotherapy, NHS, CO, International Conference on Population and Development, PFE, Pharmaceutical industry, Medical imaging

In abscopal tumors, both pelareorep monotherapy and pelareorep-radiation combination therapy led to a statistically significant increase in infiltrating anti-cancer CD8+ T cells.

Key Points: 
  • In abscopal tumors, both pelareorep monotherapy and pelareorep-radiation combination therapy led to a statistically significant increase in infiltrating anti-cancer CD8+ T cells.
  • In terms of significance, this effect was not seen with single-agent radiotherapy in either the primary or the abscopal tumors.
  • "This is a compelling finding that has the potential to be broadly applicable across multiple cancer indications and warrants further study.
  • As new Keytruda combinations from Merck emerge, Bristol-Myers Squibb has begun to tout 5-year kidney cancer data for Opdivo-Yervoy.